Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 345% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- Strong ROE of 106.4% with 26.0% net margin
- Revenue growing at 10% annually
AMGEN INC (AMGN) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $188.5 billion . Key value metrics: P/E ratio 20.5, P/B ratio 21.78, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
AMGEN INC — Fundamental Analysis Summary
AMGEN INC (AMGN) is currently trading 345% above its Graham Number of $78.57, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 20.5x.
On financial health, AMGN shows a moderate Piotroski F-Score of 6/9, and strong return on equity of 106.4% (sector average: -19.8%), and high leverage with a debt-to-equity ratio of 6.31.
StockPik's composite Value Score for AMGN is 62/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
AMGN reports a high gross margin of 65.0% (sector average: 33.5%) and a strong operating margin of 23.8%.
AMGN shows revenue growing at 10% year-over-year, with earnings growing at 89%.
AMGN pays a modest dividend yield of 2.7%.